目的 觀察蓽鈴胃痛顆粒聯(lián)合雷貝拉唑治療肝胃不和型非糜爛性反流病的臨床療效。方法 選取2019年12月—2020年10月在天津中醫(yī)藥大學(xué)第一附屬醫(yī)院就診的60例肝胃不和型非糜爛性反流病患者，按照隨機數(shù)字表法分為對照組和治療組，每組各30例。對照組口服雷貝拉唑鈉腸溶膠囊，20 mg/次，1次/d；治療組患者在對照組的基礎(chǔ)上口服蓽鈴胃痛顆粒，5 g/次，3次/d。兩組患者均治療4周。觀察兩組患者臨床療效，比較治療前后兩組患者中醫(yī)證候評分和生活質(zhì)量。結(jié)果 治療后，治療組總有效率為93.33%，明顯高于對照組的73.33%（P<0.05）；治療后，兩組患者中醫(yī)各項證候積分比治療前顯著下降（P<0.05），且治療組患者改善顯著優(yōu)于對照組（P<0.05）；治療后，兩組RQS評分均較前升高（P<0.05），且治療組明顯優(yōu)于對照組（P<0.05）。結(jié)論 蓽鈴胃痛顆粒聯(lián)合雷貝拉唑治療肝胃不和型非糜爛性反流病療效較好，可顯著改善患者臨床癥狀，具有一定的臨床推廣應(yīng)用價值。

Objective To observe the clinical efficacy of Biling Weitong Granules combined with rabeprazole in treatment of non erosive reflux disease of liver-stomach disharmony. Methods Patients (60 cases) with non erosive reflux disease of liver-stomach disharmony in the First Teaching Hospital of Tianjin University of TCM from December 2019 to October 2020 were randomly divided into control and treatment groups, and each group had 30 cases. Patients in the control group were po administered with Rabeprazole Sodium Enteric Capsules, 20 mg/time, once daily. Patients in the treatment group were po administered with Biling Weitong Granules, 5 g/time, three times daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacy was evaluated, and the TCM syndrome scores and the RQS scores in two groups before and after treatment were compared. Results After treatment, the total effective rate in the treatment group was 93.33%, which was significantly higher than 73.33% in the control group (P < 0.05). After treatment, the TCM symptom scores in two groups were significantly lower than those before treatment (P < 0.05), and the improvement in the treatment group was significantly better than that in the control group (P < 0.05). After treatment, the RQS scores in two groups were higher than those before treatment (P < 0.05), and which in the treatment group was significantly better than that in the control group (P < 0.05). Conclusion Biling Weitong Granules combined with rabeprazole has a good effect on the treatment of non erosive reflux disease of liver-stomach disharmony, which can significantly improve the clinical symptoms and has a certain clinical application value.

R975

國家重點研發(fā)計劃課題（2019YFC1709604）